Literature DB >> 22745205

Reduction in growth threshold for pulmonary metastases: an opportunity for volumetry and its impact on treatment decisions.

M N Vogel1, S Schmücker, O Maksimovic, J Hartmann, C D Claussen, M Horger.   

Abstract

OBJECTIVES: This study compares tumour response assessment by automated CT volumetry and standard manual measurements regarding the impact on treatment decisions and patient outcome.
METHODS: 58 consecutive patients with 203 pulmonary metastases undergoing baseline and follow-up multirow detector CT (MDCT) under chemotherapy were assessed for response to chemotherapy. Tumour burden of pulmonary target lesions was quantified in three ways: (1) following response evaluation criteria in solid tumours (RECIST); (2) following the volume equivalents of RECIST (i.e. with a threshold of -65/+73%); and (3) using calculated limits for stable disease (SD). For volumetry, calculated limits had been set at ±38% prior to the study by repeated quantification of nodules scanned twice. Results were compared using non-weighted κ-values and were evaluated for their impact on treatment decisions and patient outcome.
RESULTS: In 15 (17%) of the 58 patients, the results of response assessment were inconsistent with 1 of the 3 methods, which would have had an impact on treatment decisions in 8 (13%). Patient outcome regarding therapy response could be verified in 5 (33%) of the 15 patients with inconsistent measurement results and was consistent with both RECIST and volumetry in 1, with calculated limits in 3 and with none in 1. Diagnosis as to the overall response was consistent with RECIST in six patients, with volumetry in six and with calculated limits in eight cases. There is an impact of different methods for therapy response assessment on treatment decisions.
CONCLUSION: A reduction of threshold for SD to ±30-40% of volume change seems reasonable when using volumetry.

Entities:  

Mesh:

Year:  2012        PMID: 22745205      PMCID: PMC3474043          DOI: 10.1259/bjr/87835487

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  17 in total

Review 1.  Measuring agreement in method comparison studies.

Authors:  J M Bland; D G Altman
Journal:  Stat Methods Med Res       Date:  1999-06       Impact factor: 3.021

2.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors:  P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

3.  In vivo repeatability of automated volume calculations of small pulmonary nodules with CT.

Authors:  Cristiano Rampinelli; Elvio De Fiori; Sara Raimondi; Giulia Veronesi; Massimo Bellomi
Journal:  AJR Am J Roentgenol       Date:  2009-06       Impact factor: 3.959

4.  [Automated pulmonary nodule volumetry with an optimized algorithm. Accuracy at different slice thicknesses compared to unidimensional and bidimensional measurements].

Authors:  M N Vogel; R Vonthein; S Schmücker; O Maksimovich; W Bethge; V Dicken; C D Claussen; M Horger
Journal:  Rofo       Date:  2008-08-08

5.  CT tumor measurement for therapeutic response assessment: comparison of unidimensional, bidimensional, and volumetric techniques initial observations.

Authors:  Srinivasa R Prasad; Kartik S Jhaveri; Sanjay Saini; Peter F Hahn; Elkan F Halpern; James E Sumner
Journal:  Radiology       Date:  2002-11       Impact factor: 11.105

6.  Comparison of treatment response classifications between unidimensional, bidimensional, and volumetric measurements of metastatic lung lesions on chest computed tomography.

Authors:  Lien N Tran; Matthew S Brown; Jonathan G Goldin; Xiaohong Yan; Richard C Pais; Michael F McNitt-Gray; David Gjertson; Sarah R Rogers; Denise R Aberle
Journal:  Acad Radiol       Date:  2004-12       Impact factor: 3.173

7.  Statistical methods for assessing agreement between two methods of clinical measurement.

Authors:  J M Bland; D G Altman
Journal:  Lancet       Date:  1986-02-08       Impact factor: 79.321

8.  Reproducibility of temporal volume change in CT of lung cancer: comparison of computer software and manual assessment.

Authors:  O Honda; M Kawai; T Gyobu; Y Kawata; T Johkoh; J Sekiguchi; N Tomiyama; S Yoshida; H Sumikawa; A Inoue; M Yanagawa; T Daimon; H Nakamura
Journal:  Br J Radiol       Date:  2009-03-30       Impact factor: 3.039

9.  Comparison of manual and automated size measurements of lung metastases on MDCT images: potential influence on therapeutic decisions.

Authors:  Sandra Pauls; Christian Kürschner; Ekta Dharaiya; Rainer Muche; Stefan A Schmidt; Stefan Krüger; Hans-Jürgen Brambs; Andrik J Aschoff
Journal:  Eur J Radiol       Date:  2007-07-02       Impact factor: 3.528

Review 10.  Evaluation of the response to treatment of solid tumours - a consensus statement of the International Cancer Imaging Society.

Authors:  J E Husband; L H Schwartz; J Spencer; L Ollivier; D M King; R Johnson; R Reznek
Journal:  Br J Cancer       Date:  2004-06-14       Impact factor: 7.640

View more
  3 in total

1.  [Image post-processing, part 1: visualization and segmentation].

Authors:  T Baumann; M Langer
Journal:  Radiologe       Date:  2013-09       Impact factor: 0.635

Review 2.  Advances in Imaging and Automated Quantification of Malignant Pulmonary Diseases: A State-of-the-Art Review.

Authors:  Bruno Hochhegger; Matheus Zanon; Stephan Altmayer; Gabriel S Pacini; Fernanda Balbinot; Martina Z Francisco; Ruhana Dalla Costa; Guilherme Watte; Marcel Koenigkam Santos; Marcelo C Barros; Diana Penha; Klaus Irion; Edson Marchiori
Journal:  Lung       Date:  2018-10-09       Impact factor: 2.584

Review 3.  Functional imaging biomarkers for assessing response to treatment in liver and lung metastases.

Authors:  Livia Bernardin; Elizabeth A M O'Flynn; Nandita M Desouza
Journal:  Cancer Imaging       Date:  2013-12-11       Impact factor: 3.909

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.